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ABSTRACT 
The New World alphaviruses eastern equine encephalitis virus (EEEV), Venezuelan 
equine encephalitis virus (VEEV), and western equine encephalitis virus (WEEV) are all 
mosquito-borne pathogens originating in North and South America. All three viruses are capable 
of causing severe illness in animals and humans, with extreme cases leading to encephalitis. 
Given the lack of commercially available vaccines or treatments, and previous research into 
these pathogens as potential bioterrorism weapons, all three are of great significance to public 
health. The aim of our laboratory was to develop a cynomolgus macaque model to study the 
unique neuropathology of each virus when delivered via an aerosol route, the most likely 
delivery route for a biological attack. To assess pathogenesis, peripheral blood mononuclear cells 
(PBMCs) were isolated from whole blood and analyzed by flow cytometry. Inflammation in the 
central nervous system (CNS) was also evaluated using a LEGENDplex bead based 
immunological array. Results indicate a substantial increase in the number of CCR2+ myeloid 
cells in circulation, a receptor important for homing and migration to infected tissue. In addition, 
inflammatory cytokines MCP-1 (CCL-2), IP-10, IL-6, and IL-8 were substantially upregulated in 
the CNS tissues and cerebrospinal fluid (CSF) of lethally infected animals. Collectively, this 
suggests homing and migration of peripheral immune cells to the CNS, and identifies potential 
markers for future longitudinal studies of alphavirus disease progression and severity. 
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1.0  INTRODUCTION 
Eastern equine encephalitis virus (EEEV), western equine encephalitis virus (WEEV), 
and Venezuelan equine encephalitis virus (VEEV) are all members of the genus alphavirus, 
within group IV of the family Togaviridae. These three viruses are collectively called the New 
World alphaviruses because of their geographic distribution across North and South America. 
They evolved separately from another existing group known as the Old World alphaviruses, 
which include Sindbis and Semliki Forest virus. Although Old World alphaviruses are known to 
cause arthritogenic disease, the New World alphaviruses are characterized by encephalitic 
disease. As alphaviruses, EEEV, WEEV, and VEEV possess single-stranded positive sense RNA 
genomes, which contains two separate open reading frames for structural and non-structural 
genes. The alphavirus virion is composed of an icosahedral nucleocapsid with a monomer 
envelope, studded with membrane-anchored glycoproteins (E1, E2) for cell attachment and entry 
(1).  
The US Department of Agriculture (USDA) classifies both EEEV and VEEV as Select 
Agents. Although WEEV is not considered a Select Agent, as a recombinant of EEEV and a 
Sindbis-like virus, it has major implications regarding alphavirus recombination. During the 
Cold War, EEEV, WEEV, and VEEV were studied by the United States and Russia as potential 
incapacitating agents (2). As the name suggests, all three viruses cause severe neurological 
pathology in equine species such as horses, donkeys, and zebras. These alphaviruses rotate 
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through a classical arboviral transmission cycle in which various vertebrate hosts such as birds, 
rodents, equids, and non-human primates serve as reservoirs (3). Outbreaks can occur in human 
populations and are typically preceded by a substantial outbreak in nearby equine populations, 
leading to medically and economically impactful disease. Regionally, these viruses are found in 
North and South America, although each has different zoonotic potential, given differences in 
vector and reservoir species (4). Mortality for most of these alphaviruses is low (4%-5%), with 
only a small number of naturally exposed individuals developing symptoms (5). However, 
symptomatic infection can rapidly progress to encephalitis with mortality rates varying for each 
virus: ~10% for WEEV, 30-70% for EEEV, and <1% for VEEV. Of the survivors of WEEV or 
EEEV encephalitis, roughly a third experience persistent neurological damage (5). No treatment 
or vaccine exist that are approved by the US Food and Drug Administration (FDA) for any of 
these viruses, and infection with one alphaviruses does not confer cross-reactive immune 
responses. Understanding the unique pathology of each of these viruses and the means of 
neuroinvasion is essential to generating viable biological interventions, and could help further 
elucidate neuroinvasive mechanisms of other arboviruses. 
1.1 EASTERN EQUINE ENCEPHALITIS VIRUS 
1.1.1 Epidemiology 
Eastern equine encephalitis virus is separated into 4 distinct genetic lineages each 
associated with specific regions of North or South America. Lineage I is considered the North 
American strain, and ranges across the east and gulf states of the United States. Lineage II, III, 
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and IV are South American variants including those from the countries of Brazil, Venezuela, 
Peru, Columbia, and Argentina. The second lineage is thought to spread as far north as Central 
America (6). Although the geographic distribution of EEEV in North America was thought to be 
limited by colder weather conditions up north, in recent years cases have occurred as far north as 
eastern Canada (7). It was first identified as a potential human disease in 1938, when an outbreak 
in equine populations resulted in a subsequent outbreak across eastern Massachusetts (8). 
Although the infection rate in human and equine populations was low, the lethality of the virus 
was high. In horses, it is estimated that the mortality rate of the virus was 90%, and in 
symptomatic humans, it ranges from 30-70% (8, 9). According to the centers for disease control 
(CDC), on average there are roughly 6 human cases of EEEV in the US per year, but over the 
past decade there has been a resurgence of EEEV cases and an expansion of the range of the 
virus as far north as Nova Scotia and Canada (7).  
EEEV, like WEEV and VEEV, is transmitted through a classical arboviral transmission 
pathway. The primary reservoir for EEEV is thought to be passerine birds, with rodents and 
other small mammals playing minor roles. The enzootic cycle of EEEV is maintained in 
freshwater fowl, typically in swamps or marshlands. The vector primarily responsible for 
circulation within the enzootic cycle is the Culiseta melanura, which feeds almost exclusively on 
avian species. As such, in order for an epizootic outbreak to occur a bridge vector is required to 
transmit to humans or other mammals. Some mosquitoes that may facilitate this bridging of 
enzootic to epizootic cycles include Aedes, Coquillettidia, and Culex species (10). As with most 
arboviruses, outbreaks of EEEV occur in a seasonal fashion in direct relation to temperature and 
rainfall. Humans and equines are considered dead-end hosts due to insufficient virus titers in 
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blood for subsequent infection of blood feeding mosquitoes, and will be discussed at greater 
length in the section on EEEV pathogenesis.  
The major divide in classification between North American and South American strains 
of EEEV is based on antigenic properties. Infection or vaccination with one strain does not 
convey a cross-reactive immune response. Despite being an RNA virus, with expected high rates 
of mutation, EEEV is surprisingly conserved across samples (11). In comparison, the South 
American strain seems to have a more controlled rate of mutation, but is not commonly 
associated with human disease (12, 13). The North American strain may undergo periodic 
extinction events of viral strains or mutations due to low virus populations in regions with 
overwintering (12). Another distinction of the North American strain is in the enzootic cycle 
vector and host ecology. Instead of avian or mammalian reservoirs, North American EEEV may 
also utilize reptilian or amphibian hosts. These conditions could explain the genetic drift 
evolution of North American EEEV and the episodic increases in virulence.  
1.1.2 Pathogenesis 
EEEV, WEEV, and VEEV were originally thought to follow a similar pathogenesis due 
to similarities in viral life cycle, neurotropism, and genetic relationship. However, closer 
investigation into the pathogenesis of each virus has highlighted unique differences between 
New World alphaviruses. EEEV is unique in that there are little to no prodromal symptoms, 
meaning infected individuals exhibit no initial symptoms prior to the development of a full fever. 
Once symptoms have occurred, the virus has already invaded the central nervous system. 
Infected individuals typically experience non-differentiable acute febrile illness with chills, 
myalgia, arthralgia, retro-ocular pain, headache, and even loss of consciousness. From there it 
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rapidly progresses to more severe neurological disease, resulting in paralysis, seizures, coma, and 
death (14). As stated previously, mortality for symptomatic EEEV infections can range from 
30%-70%. Of the survivors, roughly one third develop long-term neurological sequelae.  
Klimstra and colleagues have suggested that, unlike VEEV or WEEV, EEEV is incapable 
of infecting most lymphoid origin cells or myeloid cells (15). The inability of EEEV to infect 
these cells types is controlled at the genetic level, rather than by cell adhesion and entry factors 
(15). Interestingly, avoidance of these tissues may reduce the production of INF-α/β in vivo, 
representing a unique evasion of host immune responses. Due to altered tropism during 
peripheral replication, EEEV does not exhibit the characteristic prodromal symptoms of most 
arboviruses. Peripheral replication seeds a viremia that reaches titers equivalent with other 
alphaviruses, but of shorter duration. Due to the high neurotropism of EEEV, this is sufficient for 
invasion of central nervous tissue and progression of encephalitis. Once in the CNS, EEEV 
replicates and neurological symptoms progress rapidly. While the exact mechanism of 
neuroinvasion remains unclear, data suggests that the virus is crossing the blood brain barrier via 
passive transfer (16).  
Like many neurotropic arboviruses, all three New World alphaviruses are particularly 
virulent in adolescent populations. It is theorized that immature neurons do not have sufficient 
expression of neuroprotective genes such as bcl-2, which inhibit caspase dependent apoptosis 
(17, 18). Neuron maturity has also been shown in vitro to alter efficiency of viral protein 
synthesis and packaging (19). Alphaviruses typically halt expression of host proteins and rapidly 
kill infected cells. Mature neurons appear to recover host protein synthesis after infection, 
whereas immature neurons do not. As is often the case with lethal viral encephalitis, death is the 
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result of inflammation in the brain causing pressure on the brain stem, thereby stopping vital life 
functions.  
1.2 VENEZUELAN EQUINE ENCEPHALITIS VIRUS 
1.2.1 Epidemiology 
VEEV was first discovered in Venezuela in 1938 (20). The virus was known to cause 
mild to severe disease in equine species, but no known human cases had occurred. Several years 
later in 1943, human cases began presenting from laboratories where VEEV isolates were being 
tested (21). It is believed that these cases were caused by aerosolization of virus during isolation, 
and VEEV has since been shown to be highly infectious by the aerosol route (22). Unfortunately, 
due to the geographic distribution throughout South and Central America, the presence of 
symptomatically indistinguishable diseases such as dengue fever, and the relative scarcity of 
specialized laboratory equipment for VEEV detection, disease burden remains largely unknown 
(23).  
VEEV strains are broken down by subtype (I-VI) with subtype I further broken down into 
variants AB, C, D, and E. Epizootic strains include IAB and IC and enzootic strains, which cause 
illness in humans but not equines, include ID, IE, and IIIA (20).  The life cycle of VEEV follows 
a classical arboviral transmission cycle with an enzootic and epizootic cycle. The enzootic cycle 
involves the cyclical transmission within reservoir (sylvatic) rodents, bats, birds, and equines 
(24). Transmission is primarily by mosquitoes with varying efficiency between species. At least 
10 species are considered probable vectors within North and South America including Aedes, 
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Culex, Psorophora, Mansonia, and Deinocerites species. Due to the low fidelity of RNA viruses, 
rapid mutation in genome can cause a sudden change of phenotype and expand host range. 
Specifically, repeated rounds of transmission within the enzootic cycle resulting in a mutation of 
the E2 glycoprotein, the primary cell attachment factor, has been shown to initiate epizootic 
outbreaks (25). Spillover from enzootic cycles can also occur during seasons of heavy rainfall, 
which causes an increase in populations of vector species. Human cases usually occur in 
individuals who work with equine or equid species during an epizootic outbreak.  
The first confirmed naturally acquired human case of VEEV was in Colombia in 1952, 
and the first confirmed naturally acquired case in the United States was 1968 (20). Outbreaks of 
VEEV have occurred sporadically from 1930-1970 throughout South America and into the 
southern United States. Major epizootic periods include Guajira Peninsula (1938-1942), 
Venezuela (1962), and Colombia (1967-1972) (26).The period from 1967-1972 caused as many 
as 100,000 equine deaths, and the infection of between 250,000 and 500,000 people (26). 
Although mortality rates for the virus remained low, the economic impact was substantial. After 
this period in the early 1970s, outbreaks of VEEV became rarer and it was believed that the virus 
was under control. Since then VEEV has re-emerged, causing outbreaks in Venezuela (1995) and 
Southern Mexico (1993-1996) (27-29). Adaptation to either reservoir species or vector, through 
variations in binding via the E2 glycoprotein, has been implied as a major determinant in the 
emergence of VEEV after a considerable period of inactivity (30).  
1.2.2 Pathogenesis 
Alphavirus infections in humans are typically asymptomatic; however, symptomatic 
infections can progress rapidly to lethal encephalitis. Of the three, VEEV is the least lethal, with 
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a mortality rate below 1% (31). The pathogenesis of VEEV demonstrates a biphasic illness 
starting with peripheral infection/replication, eventually leading to invasion of the CNS. In 
natural infections, replication begins at the site of inoculation and spreads quickly to the draining 
lymph node. Unlike EEEV, VEEV exhibits a strong tropism for dendritic cells, macrophages, 
and cells of lymphoid origin (15, 32). Although capable of infecting mesenchymal cells like 
EEEV, the primary site of replication appears to be dendritic cells originating in the skin, called 
Langerhans cells (32). These infected dendritic cells migrate to the draining lymph where the 
virus replicates rapidly, seeding viremia. This first phase is characterized by a non-descript 
febrile illness, similar to many arboviral infections. Viremia reaches relatively high titers 
compared to EEEV or WEEV and disseminates systemically, causing infection of peripheral 
lymphoid tissues. High viremia develops early in infection, but is rapidly cleared by the immune 
system. The brief viremia is sufficient for the invasion of central nervous tissue via the 
trigeminal and olfactory nerves, thereby progressing to the second phase of the disease (33). 
Although infection of the CNS in humans is rarely lethal, it is highly debilitating. Common 
symptoms include fever, headache, myalgia, arthralgia, retro-ocular pain, and chills (34). Unlike 
WEEV or EEEV, VEEV is not known to cause long-term neurological sequelae and even 
encephalitic infections have a high survival rate.  
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1.3 WESTERN EQUINE ENCEPHALITIS VIRUS 
1.3.1 Epidemiology 
 Western Equine Encephalitis Virus was first identified in the 1930 as the cause of several 
outbreaks in equine populations throughout the western United States. Several years later in 
1935, WEEV was isolated from human patients in Saskatchewan Canada (35). From1930-1950, 
sporadic outbreaks occurred across these regions often proceeded by nearby outbreaks in equine 
species by several weeks (35). Like EEEV and VEEV, WEEV follows a classical arboviral 
transmission cycle with passerine birds as the primary reservoir. The primary vector species for 
WEEV transmission is the mosquito Culex tarsalis, from which the virus has been isolated as 
early as the 1940s (36). As with most arboviral infection, a temporal relationship exists between 
abundance of vector species and WEEV transmission, resulting in most infections occurring 
during the summer (37).  
 Interestingly, since the initial period of WEEV activity, from 1930-1950, there has been a 
dramatic reduction in the number of cases each decade since (38). No additional cases have been 
reported in the US or Canada since 1998 (39). The cause of this rapid decline in infectivity is 
unclear although theories regarding environmental changes or mutations have been suggested. 
Given the low apparent mutation rate of alphaviruses, and recent experiments in animal models, 
changes in virulence does not appear to explain this trend (40). What makes WEEV unique 
compared to the other New World alphaviruses, is its origin as a recombinant virus. While the 
sequence of WEEV’s capsid protein and 3’ UTR region appear to have come from EEEV, the E1 
and E2 glycoproteins, responsible for cell adhesion and entry, appear to have close genetic 
similarity to the Old World Sindbis virus (41). Through recombination, WEEV exhibits the 
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cellular tropism of Old World Sindbis-like viruses, but retains some of EEEV’s encephalogenic 
properties. Although it has the potential for long-term neurological sequelae like EEEV, WEEV 
is substantially less lethal, with a mortality rate of less than 5% of symptomatic individuals.  
 Like EEEV, WEEV can cause long-term neurological sequelae, and, due to neuronal 
maturation, adolescents and infants appear more susceptible to infection. In addition to infants 
and adolescents being susceptible populations, elderly populations are also more prone to 
symptomatic WEEV infection. While cases have declined, WEEV remains a reportable illness 
with the potential to cause further epidemics. Considering its origin as a recombinant alphavirus, 
it also suggests possible routes of evolution for RNA viruses that could cause sudden shifts in 
infectivity or susceptibility. 
1.3.2 Pathogenesis 
 WEEV infections, like other New World alphaviruses, are often asymptomatic. Those 
who do experience illness typically present with mild flu-like symptoms: fever, myalgia, 
headache, lethargy, and stiff neck. Despite close genetic relationship to EEEV, WEEV does 
present prodromal symptoms, which is likely due to the altered E1 and E2 glycoproteins causing 
differences in peripheral infection. After prodromal symptoms, WEEV can progress to 
encephalitic disease, with higher frequency in children and elderly populations. WEEV 
encephalitis often presents with headache, vomiting, neck stiffness, altered mental state, and 
seizures.  
Neural invasion has been seen regardless of route of exposure, although the exact method 
of entry remains unclear. In addition, the olfactory bulb has been identified as a possible entry 
point, given higher viral titer in this region compared to the rest of the brain (42). WEEV 
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presents a hybrid-like pathology of EEEV and VEEV. Like VEEV it infects a number of 
peripheral cells and stimulates an adaptive response, but is also capable of developing lethal 
encephalitis similar to EEEV infection. It is unclear if the mechanism of neural invasion for 
WEEV is more like EEEV or VEEV, but given substantial difference in E1 and E2 glycoproteins 
it could present a novel mechanism entirely.   
1.4 PUBLIC HEALTH SIGNIFICANT 
1.4.1 History of New World Alphaviruses and Biological Warfare 
The New World Alphaviruses EEEV, VEEV, and WEEV pose significant threats to 
human and equine populations as naturally occurring infections, as well as potential bioterrorism 
agents. There are currently no therapeutics or interventions for New World alphavirus infection 
approved by the US food and drug administration. All three pathogens are classified as Category 
B agents by the Centers for Disease Control and Prevention (43). Although WEEV has reduced 
dramatically in frequency over the last 3 decades, as a multi-host pathogen, WEEV, EEEV, and 
VEEV all have the potential for recombination events significantly altering virulence and 
infectivity. In addition, climate change has caused dramatic changes in arthropod geographic 
distribution, life cycles, and abundance. These changes in vector species have already altered 
viral evolution and virulence for several mosquito-borne pathogens around the world, resulting 
in wide spread epidemics (44). 
VEEV was investigated during the period of operation of the United States Biological 
Warfare and Biological Defense Programs from 1942-1969 (45, 46).  US biological weapons 
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development was halted in 1969 after two national security memoranda.  Later in 1970, an 
international accord would be presented for the Convention on the Prohibition of the 
Development, Production and Stockpiling of Bacteriological (Biological) and Toxin Weapons. 
During this same period, the Soviet Union had a highly active bioweapons program, which 
designed a smallpox-VEEV chimera for aerosol transmission (2). The interest in VEEV as a 
biological weapons agent for both defensive and offensive application was as a debilitating 
agent. The bi-phasic febrile illness that is characteristic of VEEV is highly debilitating, and 
because it is non-lethal, there is reduced risk of collateral damage.  
While VEEV was of primary investigation for offensive development, WEEV and EEEV 
were also research by the United States as part of a defensive biological program. All three New 
World alphaviruses grow to high titer in stock, making production on a large scale simple and 
relatively cheap (47). Even more alarming is the ease with which reverse genetic systems can be 
utilized to genetically alter these viruses to increase virulence (48, 49). In addition, New World 
alphaviruses are highly stable in aerosol form. These aspects make EEEV, VEEV, and WEEV 
ideal targets for biological weaponization, and therefore of high concern. Given their history of 
weaponization, their potential for artificially induced virulence, potential for mortality or long-
term morbidity, expanding vector species range, and potential for co-infection and recombination 
with other arboviral species, further investigation into New World alphaviruses is essential to 
global health and security.  
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2.0  STATEMENT OF PROJECT AND SPECIFIC AIMS 
Neurological disease caused by the New World alphaviruses Eastern, Western, and 
Venezuelan Equine Encephalitis virus is poorly understood. In studying especially lethal or 
disabling pathogens that affect humans, it is necessary to establish models that can be used to 
mimic human disease as closely as possible. In the case of encephalitic alphaviruses, in order test 
vaccines, anti-virals, or other interventions, it is necessary to apply the FDA Animal Efficacy 
Rule or Animal Rule (50). This rule is applied to the development of biological interventions for 
life-threatening diseases when human efficacy trials are either infeasible or unethical. For this 
study, we built upon previous work that established cynomolgus macaques as a potential model 
for New World alphaviruses EEEV, WEEV, and VEEV. The overarching goal of the larger 
project is to identify biomarker(s) of impending viral encephalitis or disease severity in all 3 
viruses. As a first step towards this goal, we characterized the peripheral immune responses in 
cynomolgus macaques as a result of aerosol exposure to EEEV, WEEV, and VEEV. Our 
hypothesis is that there will be measurable changes in peripheral blood immune cell populations, 
blood chemistry parameters, and/or inflammatory cytokines that will correlate with the onset of 
viral encephalitis (for EEEV and WEEV) or acute febrile illness (for VEEV) as well as an 
indication of disease severity. These data, in combination with telemetry, CT-scans, and 
neurological symptoms, could be useful for identifying important clinical windows for 
intervention.  
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2.1 AIM 1: IDENTIFY CHANGE IN PERIPHERAL BLOOD LYMPHOID AND 
MYELOID POPULATIONS IN CYNOMOLGUS MACAQUES INFECTED WITH 
EEEV, VEEV, AND WEEV 
Based on previous models of alphavirus infection by aerosol route in cynomolgus 
macaques, we expect lymphopenia and granulocytosis in peripheral immune cell populations; 
however, further delineation of changes in cell populations has not been done. 
We hypothesize that, due to the importance of T cells for clearance of viral infection of 
the CNS (51), there will be a direct correlation between increased disease severity in the lethally-
infected animals and decreases in overall T cell numbers. We also predict that given the rapid 
progression of lethal EEEV infection (5-6 days), the innate immune system may play an 
important role in survival. To address this aim, comparisons will be made between pre- and 
necropsy (PRE vs NEC for lethally infected animals), pre-infection and convalescence in 
survivors (PRE vs CONV in survivors). By comparing PRE/NEC and PRE/CONV samples 
within each virus as well as between all 3 viruses, we will determine if there are major changes 
in cell populations over the course of infection.  
To address this aim, we will perform the following assays: 
1. Complete blood count (CBC) and blood chemistry analysis on blood samples from 
each animal at each time point. 
2. Isolate peripheral blood mononuclear cells (PBMCs) from whole blood prior to 
infection and at the time of necropsy. The flow cytometry staining protocol will be 
optimized in order to easily identify various lymphoid and myeloid cell populations using 
flow cytometry [T cells, NK cells, B cells, plasmacytoid dendritic cells (pDCs), myeloid 
dendritic cells (mDCs), brain homing macrophages, classical, non-classical, and 
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intermediate monocytes]. Cell numbers will be normalized to complete blood count 
(CBC) parameters and against expression of pan-leukocyte marker CD45. In addition to 
identification quantification of cell types, we will assess differences in activation marker 
expression (HLA-DR) (potential future activation markers CD81, intracellular markers 
Ki-67, or pro-inflammatory cytokine production). 
2.2 AIM 2: IDENTIFY PERIPHERAL INFLAMMATORY BIOMARKERS 
ASSOCIATED WITH LETHAL VS SUBLETHAL DISEASE IN THE PLASMA AND 
CSF, AND CORRELATE THESE FINDINGS WITH BRAIN TISSUE 
As with Aim 1, comparisons will be made between PRE/NEC and PRE/CONV samples 
from the same animal, as well as across animals infected with each of the viruses. We 
hypothesize that cytokines that are dysregulated in the brain tissues itself are also detectable in 
the serum and/or CSF. By comparing endpoint samples from necropsy to pre-infection samples, 
we will be able to detect changes in the periphery that correlate with what is happening in the 
CNS tissue. Previous work in mice suggests a hierarchy of inflammatory cytokine dysregulation 
in the periphery (VEEV>WEEV>EEEV) (1). Future studies will use the results found here to 
examine earlier (pre-necropsy) samples to identify early biomarkers of lethal encephalitis.    
To address this aim, we will obtain pre-infection and post-infection serum samples, CSF 
(from necropsy), and homogenized brain tissues from the cerebellum, frontal cortex, parietal 
lobe, occipital lobe, and temporal lobe. Samples will be analyzed for cytokine and chemokine 
expression using BioLegend’s LEGENDplex 13-parameter bead-based immunoassay. The 
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inflammatory markers we will measure include: IL-6, IL-10, CXCL10, IL-1 β, IL-12p40, IL-
17A, IFN- β, IL-23, TNF- α, IFN- γ, GM-CSF, IL-8, and CCL2. 
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3.0  MATERIALS AND METHODS 
3.1 BIOSAFETY 
All experiments using the live virulent strains V105 of EEEV, INH9813 of VEEV, and 
FLEMING of WEEV were performed in the Regional Biocontainment Laboratory at the 
University of Pittsburgh. This facility is approved by the Division of Select Agents and Toxins 
(DSAT) and the USDA to work with Tier 1 Select Agents. All work was conducted in class II 
biosafety cabinets connected to external HEPA filters, and no air was recirculated into the lab. 
Every worker was required to abide by Biosafety Level 3 practices, and use powered air 
purifying respirators (3M Versaflo TR-300 PAPR unit) within containment labs. All animal 
work was performed under Animal Biosafety Level 3 practices, and operated under strict 
institutional animal care and use committee (IACUC) approval. All animal work requiring sharps 
for EEEV or VEEV infected animals was performed by vaccinated technicians with sufficient 
antibody titers. For decontamination, Vesphene IIse in a 1:128 dilution was used with a 
minimum contact time of fifteen minutes before being marked for further decontamination via 
autoclave.  
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3.2 AEROSOL 
All aerosol infections were performed by Dr. Douglas Reed and his lab. Aerosol 
generation for each virus was performed using an Aeroneb, vibrating-mesh nebulizer. Aerosols 
were delivered to the animal in a head only exposure chamber via the AeroMP Exposure System, 
housed within a Class III biosafety cabinet. To maintain a constant breathing rate, each animal 
had a pump for continual anesthetic during the exposure. Plethysmography data were calibrated 
based on airflow changes in a chamber adjacent to the head only exposure chamber, allowing us 
to calculate the exact dose delivered to the animal based on loading titer, time, lung volume, and 
respiration rate. At this stage in the study we are attempting to identify an ID100 for each virus. 
The target titer to challenge the first animal was E+07, with subsequent infections of other 
animals being approximately 1 log above or below the first infection. Animals were necropsied 
when they met necropsy criteria or after convalescence (28 days post exposure). Animals were 
monitored by telemetry implants for ECG, EEG, and temperature, and 24/7 video surveillance 
prior to exposure, and until necropsy or until observations scored the animal at a 3 for one week. 
3.3 BLOOD DRAWS AND CELL ISOLATION 
Baseline blood samples were taken from all monkeys at the housing facility in Plum. 
Blood was collected in ethylenediaminetetraacetic acid  (EDTA) vacutainers (purple top), 
sodium heparin vacutainers (green top), and plain vacutainers (red top). Blood treated with 
sodium heparin was used for blood chemistry analysis on a Vetscan VS2 Abaxis blood chemistry 
machine. CBC data was collected from EDTA treated blood run on a Vetscan HM2 Abaxis 
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Hematology Analyzer. Blood in plain vacutainers and EDTA vacutainers was centrifuged at 
2500rpm for 10 minutes at room temperature (RT), no brake. Plasma and serum were collected 
off of each tube and stored in aliquots of either 500uL or 1mL depending on the amount of blood 
being processed.  
The remaining blood in each EDTA vacutainer was transferred to 50mL conical tubes (no 
more than 15mL blood per tube) for isolation of peripheral blood mononuclear cells (PBMC). 
Sterile RT Dulbecco’s phosphate-buffered saline (DPBS) quantum satis (QS) was added, total 
volume of 35mL. Once the blood was diluted, lymphocyte separation medium (LSM) was used 
to create a density gradient to separate mononuclear cells. For each 50mL conical of blood, 
13mL of LSM was applied as an underlay and each tube was then centrifuged at 2000rpm for 25 
minutes at RT, 3 acceleration no brake. After spinning, the buffy coat layer was extracted by 
manual pipette and transferred to fresh 50mL conical tubes. The isolated cells were washed with 
sterile RT DPBS (QS), 50mL total volume. Cells were pelleted by spinning at 1800rpm for 10 
minutes at 4˚C. The supernatant was removed and cells were resuspended by flicking. To lyse 
red blood cells 10mL of ammonium-chloride-potassium (ACK) lysis buffer was added to each 
tube and they were incubated at RT for 10 minutes. After red blooc cell (RBC) lysis, cells were 
washed with 40mL of RT DPBS and spun at 1800rpm for 10 minutes at 4˚C. The supernatant 
was discarded and cells were resuspended with 30mL of 4˚C DPBS. Then we did a slow cold 
spin to remove platelet contamination (1200rpm, 15 minutes, 4˚C, no brake). Supernatant was 
pulled out using a 10mL serological pipette and the pellet was resuspended by flicking. Finally 
we resuspended the cells to a desired concentration (3-5e^6 cells/mL target, up to 20e^6 
cells/mL) using freezing media [90% fetal bovine serum (FBS), 10% dimethyl sulfoxide 
(DMSO)]. All centrifugation done using Sorvall Legend RT benchtop centrifuge. 
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3.4 SPLEEN CELL ISOLATION 
During necropsy 0.3 grams of spleen was removed and transferred to a 50mL conical fill 
with Hanks buffered salt solution (HBSS) w/o calcium and magnesium. Spleen sample was 
transferred to LS3 for further processing and cell isolation. Spleen tissue was removed from 
50mL conical and incubated for ~1 hour at RT with a digestion (1mg/mL collagenase 1-A, and 
50µg/mL DNAse 1, in HBSS w/ Ca/Mg). Once tissue was soft enough to manual digestion, it 
was cut into smaller pieces and placed in a 15mL conical with (QS) of digestion buffer, max 
volume 7.5mL. The chopped tissue was then place on a rocker in an incubator at 37˚C (45-60 
minutes). After incubating, the tissue was further broken down using a 5mL serological pipette 
until it flowed smoothly. After the serological pipette, a manual transfer pipette was used to 
vigorously pipette up and down until it flowed smoothly. The further homogenized tissue was 
placed back on the rocker to incubate at 37˚C for 30-45 minutes. After incubation, the tubes were 
removed and cells passed through a small transfer pipette to clear any visible chunks. Next, the 
homogenized tissue was added to a fresh 50mL conical after being passed through a 40µm cell 
strainer. Any homogenized material that did not go through the filter was taken off the top and 
added directly to the 50mL conical, leaving behind large chunks caught in the cell strainer. The 
cell strainer was washed with 12mL of wash buffer consisting of 50µg/mL DNase 1 in HBSS 
w/o Ca/Mg with 3% FBS. Then cells were spun at 500g for 8 minutes at RT. Supernatant was 
removed and the cells were washed again with 18mL of wash buffer and spun at 500g for 8 
minutes at RT. The supernatant was removed and the pellet resuspended with 10mL of 80% 
stock isotonic percoll (SIP) solution and transferred to a fresh 50mL conical. Then we overlayed 
the cells with SIP layers at decreasing concentrations to form a density gradient: 10mL of 38% 
SIP, 10mL 21% SIP, and 5mL of HBSS/3% FBS. The sample was then spun at 480g for 35 
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minutes at 18˚C, acceleration 3 no brake. After the spin, the top two interphases were discarded 
and the fraction at the 3rd interphase was placed in a new 50mL conical tube. The extracted cells 
were washed with 30mL of HBSS w/o Ca/Mg w/ 3% FBS and centrifuged at 300g for 8 minutes, 
RT. The pelleted cells were resuspended by flicking and incubated at RT with 10mL of ACK 
lysis buffer for 10 minutes, swirling occasionally. After red blood cell lysis, the cells were 
washed again with 40mL of RT DPBS and spun at 1800rpm for 10 minutes at 4˚C to pellet the 
cells. The cells were resuspended in freezing media [90% FBS, 10% DMSO] and put in 1mL 
aliquots for long-term storage in liquid nitrogen after step-down freezing.  
3.5 STAINING AND FLOW CYTOMETRY 
Cells were either stained fresh from isolation or from cryopreserved cells stored after 
necropsy. Every stain used from 1-1.5 million cells per well. For fresh stains, cells resuspended 
in FACS buffer were added in 250µL increments to a 96-well V-bottom plate until desire cell 
concentration was reached. Frozen cells (1mL) were thawed, and diluted in 9mL of fluorescence 
–activated cell sorting (FACS) buffer [1XDPBS, 3% FBS, 5mM EDTA, 0.1% sodium azide] in 
order to wash off DMSO. Samples were then spun with a Sorvall Legend RT bench centrifuge at 
1800rpm, for 10 minutes at 4˚C and the supernatant removed. The pellet was resuspended in 
FACS buffer to reach the desired cell concentration and added to a 96-well V-bottom plate. The 
plate was spun at 1800rpm using a microplate swinging bucket rotor in a Rotanta 460r benchtop 
centrifuge for 5 minutes at 4˚C. Supernatant was removed by quickly inverting the plate, and 
cells were resuspended with 20µL of an antibody master-mix specific to each panel, as shown in 
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Tables 1-2. All antibodies were purchased from BD Bioscience with the exception of NKG2A 
(clone Z199), which is from Beckman Coulter. 
Table 1. Flow Cytometry Lymphocyte Panel 
Antibodies Clone Volume (µL) 
CD3-PacBlue SP34-2 2 
CD4-PE M-T477 2 
CD8-PE-Cy7 SK1 2 
HLA-DR-PerCP-Cy5.5 L243 2 
CD20-APC-H7 2H7 2 
CD45-FITC D058-1283 2 
CD16-V500  3G8 2 
NKG2A-APC (iso) Z199 2 
FACS Buffer  4 
  Total Volume 20 
 
 
 
 
 
 
 
 
 
 
 
 
 23 
Table 2. Flow Cytometry Myeloid Panel 
Antibodies Clone Volume (µL) 
CD3-APC-Cy7 SP34-2  2 
HLA-DR-PerCP-Cy5.5 L243 2 
CD20-APC-H7 2H7 2 
CD45-FITC D058-1283 2 
CD123-PE-Cy7 (leave out) 7G3 2.5 
CD1c-PE (iso) L161 2.5 
CD16-BV421 3G8 2 
CD14-V500 M5E2 3 
CCR2-AF647 (iso) 48607 2 
  Total Volume 20 
 
The antibody mix was pipetted up and down to thoroughly resuspend the cells. Next, the 
plate was incubated at 4˚C for 30 minutes. After staining, the antibody stain was diluted by 
adding 200µL of FACS buffer and the plate was spun at 1800rpm for 5 minutes at 4˚C. The wash 
was repeated again and the pellet was resuspended with 200µL of 4% PFA and transferred to a 
5mL snap cap FACS tube. The tubes were left to sit overnight at 4˚C to fix cells and inactivate 
virus before taking samples out of containment. All samples were run on an LSRII flow 
cytometer and analyzed in FlowJo version 7.6.5.  
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3.6 BIOLEGEND LEGENDPLEX 
We used a Biolegend 13-plex NHP inflammation LEGENDplex kit to analyze the levels 
of inflammatory cytokines in neural tissue, serum, and CSF is convalescent and lethally infected 
animals. Cytokines analyzed in the panel included IL-6, IL-10, CXCL10 (IP-10), IL-1β, IL-
12p40, IL-17A, IFN-β, IL-23, TNF-α, IFN-γ, GM-CSF, IL-8, and CCL2 (MCP-1). Four tissue, 
samples of 0.2 grams each were taken from frontal lobe, temporal lobe, occipital lobe, parietal 
lobe, and cerebellum. These samples were stored in 1.5mL of modified DPBS [1% FBS, 
100U/mL penicillin, 0.05mg/mL streptomycin]. The samples were stored at -80˚C before 
preparation for multiplex. The samples were fully thawed and transferred to 5mL snap cap tubes 
for homogenization we used a handheld electric homogenizer. The homogenized tissues were 
spun at 2500rpm for 10 minutes at RT. The clarified homogenate was transferred back to their 
original 2mL screw top tubes and samples were taken for further dilution and analysis. 
Convalescent animal samples were run undiluted, while animals that were lethally infected were 
run at a 1:2 dilution of sample to LEGENDplex assay buffer. The kit standard was prepared 
using 1:4 serial dilution. All kit reagents were allowed to warm to RT before use. All samples 
and standards were run in duplicate on a 96 well plate. Each well had 25µL of Assay Buffer, and 
25µL of either standard or sample (at desired dilution). Plasma samples also had an additional 
25µL of Matrix B. Mixed beads were vortexed for 1 minute before applying 25µL to each well. 
The plate was covered with a plate sealer and wrapped in aluminum foil, then shaken at 500rpm 
for 2 hours at RT. After shaking the beads were pelleted by spinning the plate at 1050rpm for 5 
minutes at RT. The supernatant was removed by quickly inverting the plate and gently blotted 
with a paper towel. The beads were washed with 200uL of LEGENDplex washing Buffer and 
spun again at 1050rpm for 5 minutes at RT. The supernatant was removed and 25µL of detection 
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antibodies was added to each well. The plate was sealed with a fresh plate sealer, wrapped in 
aluminum, and shaken at 500rpm for 1 hour at RT. After shaking, 25µL of SA-PE was 
immediately added to each well and the plate was shaken again at 500rpm for 30 minutes at RT. 
The plate was spun down at 1050rpm for 5 minutes at RT and the supernatant removed by 
quickly inverting the plate. The beads were resuspended with 150µL of Wash Buffer and 
transferred to labeled 5mL snap cap FACS tubes. All samples were run on a FACSAria flow 
cytometer by Timothy Sturgeon and analyzed using Biolegend LEGENDplex software.  
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4.0  RESULTS 
4.1 AIM 1: IDENTIFY CHANGE IN PERIPHERAL BLOOD LYMPHOID AND 
MYELOID POPULATIONS IN CYNOMOLGUS MACAQUES INFECTED WITH 
EEEV, VEEV, AND WEEV 
To assess the changes in peripheral immune cell populations, PBMCs were isolated from 
whole blood collected at pre-infection and at necropsy, as described in materials and methods 
3.3. These cells were stained to identify lymphoid, and myeloid lineages (Figures 1, 2). Cell 
count for the lymphoid stain was calculated as a percentage of the parent population (CD45 high, 
forward scatter low, side scatter low, minus monocyte spillover). CD45 is a commonly expressed 
pan-leukocyte marker, which is found in abundance on lymphocytes, monocytes, and 
granulocytes, but not on mature erythrocytes. Because granulocytes are pelleted during the LSM 
gradient separation step, they are absent from the FACS analysis. The lymphocytes are easily 
identified by their small size and granularity on a side scatter by forward scatter analysis. There 
can still be overlap with the monocyte population, which was identified as being CD3(-),  
CD20(-), CD8(-), HLA-DR+. These monocytes were subtracted from the total CD45(+) gate to 
generate the parent population. Cell count for the myeloid stain was calculated as a percentage of 
Gate 4 (HLA-DR+, Lineage-). HLA-DR is an MHC Class II cell surface receptor predominantly 
found on antigen presenting cells. B cells and T cells are also capable of expressing HLA-DR at 
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relatively high rates, so these cells are excluded as part of the Lineage+ positive population using 
CD3 (T cell marker) and CD20 (B cell marker). Only cells that are HLA-DR+, CD3-, and CD20- 
are considered part of the myeloid lineage, which is used as the parent population.  
 
 
Figure 1. Gating Strategy for Lymphocyte Populations from PBMC 
Gate 1 (morphology), identifies lymphocytes as a forward scatter and side scatter low population. Gate 2 (doublet 
exclusion), removes clumped cells from analysis, which may fluoresce in multiple channels, as being non-linear on a 
FSC width, by FSC height graph. Gate 3 (CD 45 high), selects for cells positive for pan-leukocyte marker CD45. 
Gate 4 identifies CD20 and HLA-DR double positive cells from the CD45 high expression population. CD45 high 
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cells were divided based on CD3 expression for further analysis. CD3- cells are further gated down to identify 
CD8+, CD20-, CD16(+ or -), and NKG2A(+) cells. CD3+ cells were separated based on CD4 and CD8 expression.  
 
 
 
Figure 2. Gating Strategy for Myeloid Populations from PBMC 
Gate 1 (morphology), identifies monocytes based on size and granularity. Gate 2 (doublet exclusion), removes 
clumped cell from analysis, which may fluoresce in multiple channels, as being non-linear on a FSC width, by FSC 
height graph (Doublets also excluded by SSC width, by SSC height, graph not shown). Gate 3 (CD45 high), selects 
for cells positive for pan-leukocyte marker CD45. Gate 4 identifies CD45 expressing cells that are positive for HLA-
DR, but (lineage -) negative for CD3 and CD20. This population is further broken down by CD16 and CD14 to 
identify sub-classifications of monocytes: classical (CD14+/CD16-), non-classical (CD14-/CD16+), intermediate 
(CD14+/CD16+), and double negative DN (CD14-/CD16-). To identify plasmacytoid dendritic cells (pDCs), DN 
monocytes were analyzed for CD123 expression. Myeloid dendritic cells (mDCs) were isolated from the non-
classical population as being CD1c positive. Classical and intermediate monocyte populations were also analyzed 
for CCR2 expression levels. Gating for mDC, pDC, and CCR2 were all based on isotype controls.  
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 Five animals in total were challenged with EEEV by aerosol route. Of those animals, two 
(M161 and M163) reached sacrifice criteria by day 6 post infection, while the other three (M123, 
M160, M162) survived through to convalescence and were necropsied greater than 27 DPI. 
M160 was the first animal infected for the study and it was unclear if the animal received the 
desired dose during infection. As a result, it was decided to re-challenge the animal, which it also 
survived. M160 was eventually necropsied 19 days post secondary infection. All EEEV 
infections, doses, and outcomes can be found in Table 3.  
 
Table 3. EEEV Animal, Virus, Dose, and Outcome 
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Figure 3. Change in Peripheral Immune Populations, Lymphoid Lineage (EEEV).  
Monkeys infected with EEEV had blood collected at pre-infection and at necropsy. PBMCs were isolated from these 
samples and stained to identify lymphoid lineage cells. Percentages were calculated for B cells and NK cells using 
CD45 high cells minus monocyte cells (CD3-, CD20-, CD8-, HLA-DR+) as the parent population. T cell population 
subsets were calculated as a percentage of CD3+ cells to reduce percentage fluctuation as the result of changes in 
other lymphoid populations. 
 
Although insufficient animal numbers exists for robust statistical analysis, a number of trends are 
apparent in comparing pre-infection samples to necropsy for lethally infected animals. CD4 T 
cells appear to increase in number, whereas CD8 and CD4/CD8 double positive populations drop 
during the course of lethal infection (Figure 3). NK cell populations also appear to decrease in 
lethally infected animals. It is difficult to identify any definitive trends in B cell populations at 
this time, although serological analysis in the future may elucidate unique differences. It is 
impossible to rule out the likelihood that similar trends are also occurring in convalescent 
animals at earlier time points. Bracketing of lethal animals is purely for visual separation. 
Because of differences in time points of necropsy samples, lethal and convalescent samples were 
not statistically compared to one another for any animals or viruses.  
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Figure 4. Change in Peripheral Immune Populations, Myeloid Lineage (EEEV) 
Monkeys infected with EEEV had blood collected at pre-infection and at necropsy. PBMCs were isolated from these 
samples and stained to identify myeloid lineage cells. Percentages were calculated using HLA-DR+, CD3-, CD20- 
cells as the parent population. Difference between necropsy and pre-infection shows how progression of the disease 
alters peripheral immune populations.  
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Figure 5. Change in Peripheral Immune Populations, Myeloid Lineage continued (EEEV) 
Monkeys infected with EEEV had blood collected at pre-infection and at necropsy. PBMCs were isolated from these 
samples and stained to identify myeloid lineage cells. Percentages were calculated using HLA-DR+, CD3-, CD20- 
cells as the parent population. Difference between necropsy and pre-infection shows how progression of the disease 
alters peripheral immune populations. 
 
These data tentatively suggests that non-classical (CD16+, CD14-) and double negative 
(CD16-, CD14-) monocyte populations decrease in lethally infected animals over the course of 
infection (Figure 4). Convalescent animals exhibit no trends in intermediate, double negative, 
non-classical, or classical monocyte populations when comparing pre-infection to necropsy 
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(Figures 4, 5). It is difficult to identify trends in more specialized populations such as mDCs and 
pDCs because of their relative lack of abundance compared to other leukocytes in the blood. It 
appears that classical (CD16-, CD14+) decrease and intermediate (CD16+, CD14+) monocyte 
populations increase in lethally infected animals over the course of infection (Figure 5). 
Furthermore, the percentage of CCR2+ cells within both of these populations is also increased 
during disease course (Figure 5). CCR2 is a receptor that recognizes the chemokine CCL2, 
which drives leukocyte homing and migration toward infected tissues. The high expression of 
CCR2 on these cell types indicates active migration of these cell types, although activation and 
migration of other leukocytes cannot be ruled out through other homing markers. Although 
gating and analysis are not shown, CCR2 is not upregulated in non-classical or double negative 
monocyte populations for lethal or convalescent animals.  
Four animals have been challenged by aerosol route with VEEV so far in this study 
(M164, M165, M170, and M171). All four survived infection and were sacrificed at later dates 
(26DPI, 27DPI, 28DPI, and 29DPI respectively). The doses and outcomes can be found in Table 
4.  
Table 4. VEEV Animal, Virus, Dose, and Outcome 
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Figure 6. Change in Peripheral Immune Populations, Lymphoid Lineage (VEEV) 
Monkeys infected with VEEV had blood collected at pre-infection and at necropsy. PBMCs were isolated from 
these samples and stained to identify lymphoid lineage cells. Percentages were calculated for B cells and NK cells 
using CD45 high cells minus monocyte cells (CD3-, CD20-, CD8-, HLA-DR+) as the parent population. T cell 
population subsets were calculated as a percentage of CD3+ cells to reduce percentage fluctuation as the result of 
changes in other lymphoid populations. Difference between necropsy and pre-infection shows how progression of 
the disease alters peripheral immune populations. No animals succumbed to infection. 
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It is difficult to identify trends from changes in lymphoid populations during VEEV 
infection without lethal infection or earlier time points. One potential trend is the reduction in 
NK cells when comparing convalescence with pre-infection samples (Figure 6). All animals 
exhibited the characteristic biphasic fever associated with VEEV infection, with varying levels 
of severity. 
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Figure 7. Change in Peripheral Immune Populations, Myeloid Lineage (VEEV) 
Monkeys infected with VEEV had blood collected at pre-infection and at necropsy. PBMCs were isolated from 
these samples and stained to identify myeloid lineage cells. Percentages were calculated using HLA-DR+, CD3-, 
CD20- cells as the parent population. Difference between necropsy and pre-infection shows how progression of the 
disease alters peripheral immune populations. No animals succumbed to infection.  
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Figure 8. Change in Peripheral Immune Populations, Myeloid Lineage Continued (VEEV) 
Monkeys infected with VEEV had blood collected at pre-infection and at necropsy. PBMCs were isolated from 
these samples and stained to identify myeloid lineage cells. Percentages were calculated using HLA-DR+, CD3-, 
CD20- cells as the parent population. Difference between necropsy and pre-infection shows how progression of the 
disease alters peripheral immune populations. No animals succumbed to infection.  
 
 
 Infection with VEEV presents several noticeable trends within myeloid lineage 
populations. There appears to be consistent increases in DN, non-classical, pDC (Figure 7), and 
intermediate monocyte populations, as well as a decrease in the classical monocyte population 
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(Figure 8). Similar to EEEV, there also appears to be an increase in the expression of CCR2 on 
classical and intermediate monocytes indicating immune trafficking (Figure 8).  
 Four animals have been challenged by aerosol route with WEEV so far in this study 
(M166, M167, M168, and M169). M169 reached sacrifice criteria on day 7 post infection. The 
other animals survived the challenge and were sacrificed at later dates (29DPI, 31DPI, and 
28DPI respectively). The doses and outcomes can be found in Table 5. 
 
Table 5. WEEV Animal, Virus, Dose, and Outcome 
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Figure 9. Change in Peripheral Immune Populations, Lymphoid Lineage (WEEV) 
Monkeys infected with VEEV had blood collected at pre-infection and at necropsy. PBMCs were isolated from 
these samples and stained to identify lymphoid lineage cells. Percentages were calculated for B cells and NK cells 
using CD45 high cells minus monocyte cells (CD3-, CD20-, CD8-, HLA-DR+) as the parent population. T cell 
population subsets were calculated as a percentage of CD3+ cells to reduce percentage fluctuation as the result of 
changes in other lymphoid populations. Difference between necropsy and pre-infection shows how progression of 
the disease alters peripheral immune populations. 
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Figure 10. Change in Peripheral Immune Populations, Myeloid Lineage (WEEV) 
Monkeys infected with VEEV had blood collected at pre-infection and at necropsy. PBMCs were isolated from 
these samples and stained to identify myeloid lineage cells. Percentages were calculated using HLA-DR+, CD3-, 
CD20- cells as the parent population. Difference between necropsy and pre-infection shows how progression of the 
disease alters peripheral immune populations.  
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Figure 11. Change in Peripheral Immune Populations, Myeloid Lineage Continued (WEEV) 
Monkeys infected with VEEV had blood collected at pre-infection and at necropsy. PBMCs were isolated from 
these samples and stained to identify myeloid lineage cells. Percentages were calculated using HLA-DR+, CD3-, 
CD20- cells as the parent population. Difference between necropsy and pre-infection shows how progression of the 
disease alters peripheral immune populations.  
 
 
It is difficult to identify any obvious trends in the lymphoid or myeloid lineage 
populations in convalescent or lethally infected animals. As is consistent from myeloid lineage 
data from EEEV and VEEV, increases in intermediate monocyte population as well as CCR2 
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positive classical and intermediate populations may be a trend in WEEV infection (Figure 11). 
Again the bracketing to identify lethally infected animals is for visual purposes only, and does 
not represent any statistical comparison. 
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Figure 12. Difference in Brain Homing Monocyte Populations Between EEEV and WEEV 
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Monkeys infected with EEEV and WEEV had blood collected at pre-infection and at necropsy. PBMCs were 
isolated from these samples and stained to identify myeloid lineage cells. Percentages were calculated using HLA-
DR+, CD3-, CD20- cells as the parent population. Difference between necropsy and pre-infection for CCR2+ 
classical and intermediate monocytes indicates a trend of active homing and migration of these cell types toward 
infected tissue.  
 
While not statistically comparable, and in lieu of uninfected controls, animals lethally 
infected with EEEV and WEEV exhibit similar trends in terms of CCR2 driven classical and 
intermediate monocyte trafficking (Figure 12). It is more than likely that convalescent animals 
exhibit similar trends during peak infection, but the degree and timing of CCR2 upregulation 
may be a quantifiable marker of disease progression or severity once longitudinal samples are 
collected.  
CBC analysis was done on pre-infection and necropsy blood samples using an Abaxis 
Vetscan HM2, and a Vetscan VS2 blood chemistry machine was used to analyze blood 
chemistry markers for each animal at each time point.  
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Figure 13. CBC and Significant Blood Chemistry (EEEV) 
Blood test results for animals challenged with EEEV by aerosol delivery route. Samples tested pre-infection and at 
necropsy. Parameters of interest include lymphocytes (LYM), monocytes (MON), granulocytes (GRA), blood urea 
nitrogen (BUN), and globulin (GLOB). LYM, MON, and GRA shown as absolute count and as percentages. Pre-
infection samples from multiple blood draws was compared to necropsy samples using a student t-test (*p < 0.05; 
**p<.01; ***p<0.001). 
 
 
 As expected by previous work from Reed and colleagues, monkeys lethally challenged 
by aerosolized EEEV exhibited lymphopenia, and granulocytosis (52). Other significant shifts as 
a result of lethal infection included blood urea nitrogen and globulin (Figure 13). Blood urea 
nitrogen is typically filtered out of the blood by the kidneys as a means to remove nitrogen from 
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the body. As such, it is a measure of kidney functionality and increased levels of BUN can 
indicate heart failure, dehydration, or kidney damage. Typically, when kidney function is 
impaired BUN elevation coincides with the elevation of creatinine levels in the blood.  
Creatinine is the product of metabolic breakdown of creatine phosphate, an energy storage 
molecule found in muscle tissue. As shown in figure 14, although lethally infected animals did 
experience an elevation in creatinine blood levels it was not statistically significant. Globulin is a 
collective population of proteins found in the blood that help facilitate transport of proteins 
across lipid barriers, clotting, and general circulation health. High globulin levels is again an 
indication of dehydration, but can also be elevated during inflammation, viral infection, and 
kidney disease to name a few. Because of differences in necropsy time points between 
convalescent and lethally infected animals no statistical comparisons were made between these 
groups. Bracketing of animals serves only to visually identify the two groups. 
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Figure 14. CBC and Blood Chemistry Trends (EEEV) 
Blood test results for animals challenged with EEEV by aerosol delivery route. Samples tested pre-infection and at 
necropsy. Parameters of interest include platelet count (PLT), procalcitonin (PCT), alkaline phosphatase level 
(ALP), and creatinine (CRE). Pre-infection samples from multiple blood draws was compared to necropsy samples 
using a student t-test.  
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A general trend can be observed for animals lethally infected with EEEV suggesting 
thrombocytopenia and a decrease in procalcitonin levels. Thrombocytopenia could be indicative 
over activation of clotting factors resulting in a decrease of available platelets in the blood. It is 
unclear why a reduction in procalcitonin levels may occur during lethal infection since issues 
like sepsis and pro-inflammation are typically associated with elevation of procalcitonin. 
Alkaline phosphatase (ALP) is tested to determine liver function. Elevated ALP levels can 
indicate liver damage or dysfunction. In this case, a reduction in ALP activity may indicate 
malnutrition. As mentioned above, creatinine is another indication of kidney function and minor 
elevations can indicate dehydration. Collectively, the blood chemistry data suggests a common 
trend of dehydration and malnutrition in lethally infected animals.  Late stage pathology of 
EEEV is characterized by increasingly severe neurological symptoms and as a result, we saw a 
substantial decrease in food and water intake in these animals. The loss of appetite and reduced 
water intake could explain the trends we see in the blood chemistry data.  
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Figure 15. CBC and Blood Chemistry Trends (VEEV) 
Blood test results for animals challenged with EEEV by aerosol delivery route. Samples tested pre-infection and at 
necropsy. Parameters of interest include lymphocytes (LYM), monocytes (MON), granulocytes (GRA). LYM, 
MON, and GRA shown as absolute count and as percentages. Pre-infection samples from multiple blood draws was 
compared to necropsy samples using a student t-test. 
 
 49 
No statistically significant changes in CBC occurred in animals challenged with VEEV 
by aerosol route (Figure 15). As was noted in the VEEV flow data analysis, without lethal 
challenge for comparison it is difficult to identify important variations in immune response. 
Earlier time points may better elucidate unique changes during disease course. The blood 
chemistry parameters were also unremarkable. A student t-test was run on all CBC and blood 
chemistry parameters to confirm non-significance. 
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Figure 16. CBC and Blood Chemistry Trends (WEEV) 
Blood test results for animals challenged with EEEV by aerosol delivery route. Samples tested pre-infection and at 
necropsy. Parameters of interest include lymphocytes (LYM), monocytes (MON), granulocytes (GRA). LYM, 
MON, and GRA shown as absolute count and as percentages. Pre-infection samples from multiple blood draws was 
compared to necropsy samples using a student t-test. 
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 No statistically significant shifts in peripheral immune populations occurred in WEEV 
infected animals (Figure 16). More animals and earlier time points may help identify significant 
shifts in peripheral immune populations and blood chemistry parameters. Bracketing of 
convalescent and lethally infected animals is for visual identification purposes only, and does not 
represent a statistical comparison.  
4.2 AIM 2: IDENTIFY PERIPHERAL INFLAMMATORY BIOMARKERS 
ASSOCIATED WITH LETHAL VS SUBLETHAL DISEASE IN THE PLASMA AND 
CSF, AND CORRELATE THESE FINDINGS WITH BRAIN TISSUE 
During viral encephalitis, death can occur when swelling from inflammation places 
sufficient pressure on the brainstem to cease function. Alternatively, viral replication can cause 
cytotoxicity and destruction of neuronal cells, damaging the integrity of the CNS. The brainstem 
regulates vital bodily functions such as respiration and heart rate. It is unclear if the degree of 
inflammation is the result of viral replication or overactive immune responses, but the severity of 
inflammation may be an indicator of disease progression or potential lethality. In addition, the 
types of inflammatory cytokine upregulation may also provide information regarding the route of 
neuroinvasion. Certain inflammatory cytokines are known to cause vascular leakage and to 
weaken the blood brain barrier (53, 54). By looking at the inflammatory environment in brain 
tissue and correlating that with cerebrospinal fluid (CSF) and plasma, we may be able to identify 
trends in accessible peripheral samples that indicate progression in the CNS.  
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Figure 17. Biolegend LEGENDplex by Brain Region (EEEV) 
Brain sections (0.3g in weight) collected from monkeys during necropsy were placed in 1.5mL of 1% DPBS with 
penicillin/streptomycin and stored at -80˚C. Samples were later thawed and homogenized using a handheld electric 
homogenizer. The homogenate was spun at 2500rpm, for 10 minutes at room temperature. Clarified supernatant was 
collected and used for LEGENDplex assay. Samples from survivors were analyzed without dilution, while samples 
from lethally infected animals were diluted 1:2 in LEGENDplex assay buffer. Scale is in pg/mL. Monkeys M161 
and M163 were lethally challenged with EEEV; M123, M160, and M162 were survivors.  
 
 Samples taken from lethally infected monkeys show high levels of expression of 
inflammatory cytokines IL-6, IP-10, IL-8, and MCP-1 (Figure 17). MCP-1 or Monocyte 
Chemoattractant Protein 1 is also referred to as CCL2, the ligand responsible for attracting 
monocytes, memory T cells, and dendritic cells via the surface receptor CCR2. The increase of 
CCL2 (MCP-1) in the brains of lethally infected monkeys suggests that the observed increase of 
CCR2 on monocyte populations is leading to CNS homing and migration. It is impossible to rule 
out the possible of homing to other tissues as well without broad tissue cytokine expression 
analysis, but leukocyte neuroinvasion is a significant factor in the development of viral 
-Convalescent 
-Lethal 
 53 
encephalitis. MCP-1 is also known to affect the integrity of the blood brain barrier (55). 
Depending on the timing of upregulation of this cytokine during disease pathogenesis, this could 
be a major factor in viral entry into the CNS or cause permeabilization after viral entry. IP-10, 
also known as CXCL10, is another chemoattractant for monocytes/macrophages, T cells, NK 
cells, and dendritic cells, which interacts with CXCR3. Monocytes, fibroblasts, and endothelial 
cells typically secrete IP-10 as a response to IFN-γ.  
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Figure 18. Inflammatory Cytokine Expression in CNS (EEEV) 
Brain sections (0.3g in weight) collected from monkeys during necropsy were placed in 1.5mL of 1% DPBS with 
penicillin/streptomycin and stored at -80˚C. Samples were later thawed and homogenized using a handheld electric 
homogenizer. The homogenate was spun at 2500rpm, for 10 minutes at room temperature. Clarified supernatant was 
collected and used for LEGENDplex assay. Samples from survivors were analyzed without dilution, while samples 
from lethally infected animals were diluted 1:2 in LEGENDplex assay buffer. Data from survivors and lethally 
infected animals was averaged. No statistical comparison were made between these groups. 
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 Averages from convalescent samples and lethal samples are graphically shown to 
demonstrate the magnitude of expression at both time points (Figure 18). No uninfected control 
data is available at this stage of the project because of the destructive nature of sample collection 
for this analysis. Later stages of the project will include uninfected animals for statistical 
comparison. It is likely that expression levels for most of these cytokines is substantially lower in 
uninfected animals. Studies looking at the CNS or CSF for uninfected animals show levels of 
inflammatory expression ranging from 10^2 to 10^0 depending on the cytokine in question (56). 
Future uninfected samples will be analyzed to verify these findings and as statistical comparison 
 In addition to MCP-1 and IP-10 elevated expression, IL-6 and IL-8 are also elevated in 
lethally infected animals (Figures 17,18). IL-6 is responsible for stimulating the synthesis of 
acute phase proteins (APP), a part of the innate immune system. APPs are typically released by 
the liver in response to inflammatory cytokines and promote innate immune pathways such as 
complement fixation, C-reactive protein activation, and clotting factor activation to name a few. 
IL-8 is another cytokine that activates APPs during the febrile response and promotes 
inflammation. Both IL-6 and IL-8 can be secreted by macrophages as a result of pattern 
recognition receptor activation. In addition to innate modulation, IL-8 also plays a role in the 
chemotaxis of granulocytes, specifically neutrophils as well as their degranulation.  Interestingly, 
the frontal lobe of both lethally infected animals shows little to no inflammatory cytokine 
expression.  
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Figure 19. Biolegend LEGENDplex of Cerebrospinal Fluid and Plasma (EEEV) 
CSF taken at necropsy and plasma taken either pre-infection or at necropsy were analyzed by LEGENDplex for 
expression levels of inflammatory cytokines. All plasma samples diluted 1:4 in LEGENDplex assay buffer. Lethally 
infected animal CSF samples were diluted 1:2 in LEGENDplex assay buffer; survivor CSF was run undiluted. 
Concentration shown in pg/mL. 
 
 The CSF taken from lethally infected animal M161 closely resembled inflammatory 
cytokine expression in the brain, indicating the CSF may be a useful means for identifying viral 
encephalitis progression. Unfortunately, CSF was not successfully extracted from M163 during 
necropsy, making comparative analysis impossible. In addition, although M161 plasma taken at 
necropsy also indicates a strong parallel between peripheral cytokines and CNS inflammation, 
plasma from M163 at necropsy does not. Another important note is that, although we consider 
the survivors convalescent at this point, there is an obvious increase in inflammatory cytokines in 
plasma taken from necropsy compared to pre-infection. Although the difference is not 
statistically significant because of variations between animals, it indicates that nearly a month 
later, and with no infectious virus detected by plaque assay, these animals are not fully 
recovered.  
 
 
-Lethal 
Convalescent 
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Figure 20. Biolegend LEGENDplex by Brain Region (VEEV) 
Brain sections (0.3g in weight) collected from monkeys during necropsy were placed in 1.5mL of 1% DPBS with 
penicillin/streptomycin and stored at -80˚C. Samples were later thawed and homogenized using a handheld electric 
homogenizer. The homogenate was spun at 2500rpm, for 10 minutes at room temperature. Clarified supernatant was 
collected and used for LEGENDplex assay. All samples run without dilution. Scale is in pg/mL. No animals 
succumbed to VEEV infection, all samples taken at convalescence. IL-23 beads had reduced numbers or were 
absent in a number of samples, represented here by the two blank squares for M171 samples.  
 
 Although no VEEV animals ultimately succumbed to infection, a substantial amount of 
inflammation remains present in the brain. In EEEV and WEEV the distribution of inflammatory 
markers was fairly uniform throughout the brain, but in the case of VEEV there appears to be 
localized distribution (Figure 20). Although this could be the result of unequal recovery times for 
different brain regions, it could also be a unique difference resulting from the method in 
neuroinvasion. Although the exact method of neural invasion by EEEV and WEEV is unknown, 
one theory is that passive diffusion after permeabilization of the blood brain barrier is the cause, 
explaining a uniform distribution of inflammation. VEEV on the other hand, is theorized to gain 
viral entry through infiltrating dendritic cells from peripheral tissues (33). In addition, VEEV 
monkeys exhibit no upregulation of IL-6. This could support the theory that IL-6 levels recover 
 57 
quickly as animals become convalescent, or it could indicate that VEEV infected animals do not 
experience an elevation in IL-6 expression as is seen with EEEV and WEEV.  
The upregulation of IL-23 and IL-12p40 in some animals represents a pattern not seen in 
EEEV and WEEV infected animals. IL-23 is typically associated with activation of a Th17 
response thereby promoting inflammation. IL-23 is a heterodimer (IL-23p19 and IL-12p40) that 
binds to the IL-23 receptor, another heterodimer composed of IL-12R β1 and IL-23R. The 
changes in IL-23 expression shown here are still under review considering a possible problem 
with the LEGENDplex kit used for the assay.. IL-12p40, as a subunit of IL-23. It is secreted by 
activated macrophages and serves as an inducer for a Th1 response. IL-12p40 is important in 
sustaining effector T cell numbers in order to establish a memory population, but overexpression 
in the brain has been implicated with neurodegenerative disorders such as multiple sclerosis. 
 
Figure 21. Biolegend LEGENDplex of Cerebrospinal Fluid and Plasma (VEEV) 
CSF taken at necropsy and plasma taken either pre-infection or at necropsy were analyzed by LEGENDplex for 
expression levels of inflammatory cytokines. All plasma samples diluted 1:4 in LEGENDplex assay buffer; CSF 
was run undiluted. Concentration shown in pg/mL. 
 
 Inflammatory markers in the CSF demonstrate close parallels with CNS inflammation. 
Plasma taken at necropsy represents a poor surrogate of CNS inflammation, as is the case with 
EEEV and WEEV samples. Although it has some similarities to CNS inflammation, it is 
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inconsistent with the inflammation seen in the brain regions and CSF. There is also inconsistency 
of upregulation of inflammation markers in the plasma between animals.  
 
Figure 22. Biolegend LEGENDplex by Brain Region (WEEV) 
 
Brain sections (0.3g in weight) collected from monkeys during necropsy were placed in 1.5mL of 1% DPBS with 
penicillin/streptomycin and stored at -80˚C. Samples were later thawed and homogenized using a handheld electric 
homogenizer. The homogenate was spun at 2500rpm, for 10 minutes at room temperature. Clarified supernatant was 
collected and used for LEGENDplex assay. Samples from survivors were analyzed without dilution, while samples 
from lethally infected animals were diluted 1:2 in LEGENDplex assay buffer. Scale is in pg/mL. Monkey M169 was 
lethally challenged with WEEV; M166, M167, and M168 were survivors.  
 
Inflammatory activation in animals lethally infected with WEEV demonstrates an almost 
identical pattern to that observed for lethal EEEV infection. Once again MCP-1, IL-8, IL-6, and 
IP-10 are elevated throughout the brain of the lethally challenged animal. The striking similarity 
is not entirely unexpected when considering WEEV’s genetic origin as a recombinant of Sindbis-
like virus and EEEV.  
-Convalescent 
-Lethal 
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Figure 23. Inflammatory Cytokine Expression in CNS (WEEV) 
Brain sections (0.3g in weight) collected from monkeys during necropsy were placed in 1.5mL of 1% DPBS with 
penicillin/streptomycin and stored at -80˚C. Samples were later thawed and homogenized using a handheld electric 
homogenizer. The homogenate was spun at 2500rpm, for 10 minutes at room temperature. Clarified supernatant was 
collected and used for LEGENDplex assay. Samples from survivors were analyzed without dilution, while samples 
from lethally infected animals were diluted 1:2 in LEGENDplex assay buffer. Data from survivors was averaged. 
No statistical comparison was made between these samples due to differences in time points. 
 
As was the case with EEEV, we see a similar elevation in MCP-1, IP-10, IL-8, and IL-6 
(Figure 23). In general, although the pattern of cytokine expression appears similar, the animals 
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lethally infected with EEEV exhibit higher concentrations of these four inflammatory cytokines 
when directly compared to WEEV (4-5 fold difference), which could explain the difference in 
mortality rate between the two viruses although more animals are needed to for a sufficient 
statistical comparison. 
 
Figure 24. Biolegend LEGENDplex of Cerebrospinal Fluid and Plasma (WEEV) 
CSF taken at necropsy and plasma, taken either pre-infection or at necropsy, were analyzed by LEGENDplex for 
expression levels of inflammatory cytokines. All plasma samples diluted 1:4 in LEGENDplex assay buffer. Lethally 
infected animal (M169) CSF sample was diluted 1:2 in LEGENDplex assay buffer; convalescent CSF was run 
undiluted. Concentration shown in pg/mL. 
 
The concentration of inflammatory cytokines in the CSF in a similar pattern to the brain 
of the lethally challenged animal again demonstrates that continuing inflammatory dysregulation 
is occurring even after virus is no longer detectable by plaque assay (Figure 24). It is unclear if 
the residual inflammatory response is the result of latent virus in immune privileged tissues, or 
simply a gradual return to homeostasis. Similar to EEEV and VEEV, we see that plasma taken at 
necropsy is an inconsistent surrogate for CNS inflammation. Although it shows upregulation of 
similar inflammatory cytokines in some animals, it is not consistent with the CSF or brain 
regions. It remains to be seen if this holds true at earlier time points, or if the expression of 
inflammatory markers in the plasma occurs in a delayed fashion relative to the CNS. IL-6 is only 
-Convalescent 
-Lethal 
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elevated in the CSF of the lethally infected animal. The other inflammatory markers associated 
with the CNS are minimally elevated in the CSF of one or more survivors, but IL-6 is only 
present in the animal with active and lethal infection. This could imply that IL-6 represents a 
marker of severity of CNS inflammation as compared to the other elevated markers. If true, 
reduction in IL-6 expression during disease course could also be an indication of survival and 
recovery, even if other inflammatory markers remain elevated.  
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5.0  DISCUSSION 
New World alphaviruses are important arboviral pathogens with the potential for further 
geographical spread and severe impact to human health. Epizootic outbreaks cause substantial 
harm to equine populations and have the potential to cause human infection (4). Human disease 
can range in severity from minor febrile illness to severe encephalitis and death, and survivors 
can develop long-term neurological sequelae (1). Even in the case of VEEV, which has less than 
1% mortality rate, debilitating disease has the potential to cause significant economic disruption. 
The USDA classifies EEEV and VEEV as Select Agents because of the severe threat they pose 
to human and animal health (57). In addition, NIAID classifies all three pathogens as Category B 
priority emerging infectious diseases (58). Both these classifications recognize the threat New 
World alphaviruses pose through bioterrorism or natural outbreaks. In order to address this 
threat, it is important to understand the pathogenesis of each virus to identify potential targets for 
therapeutics or vaccines.  
No FDA approved vaccines or treatments currently exist for these viruses, and given their 
morbidity, human trials are unethical. As such, a primate model is paramount to the development 
and testing of novel therapeutics, utilizing the FDA animal rule. The ongoing goal of this study is 
to develop a non-human primate model for alphavirus infection by an aerosol route. The initial 
phase of this project was to observe complete disease progression, develop an ID100 for each 
virus, and identify potential quantifiable markers of disease severity. 
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It is important to note that longitudinal samples were not collected in order to observe 
disease progression without confounding variables. As a result, the final time points of the study 
are not directly comparable. Samples collected from animals at convalescent are not comparable 
to lethally infected samples because of differences of 2 weeks or more between time points. It is 
impossible to rule out the possibility that the same trends and patterns seen in lethally infected 
animals also occurs in convalescent animals at earlier time points. In addition, although markers 
identified at this stage of the study will be scrutinized later during longitudinal sample collection, 
it is possible that late stage disease effects on cytokines or peripheral immune population trends 
are entirely different at earlier stages. Although we may focus on trends in CCR2 cells, and 
cytokines CCL2, IP-10, IL-8, and IL-6, it will be important to continue taking a broad approach 
to sample collection and data analysis to avoid missing quantifiable markers not identified by 
this study.  
 One unique aspect of this study is the method by which the viral stocks were produced. 
As shown by Klimstra and colleagues (59, 60), alphaviruses passaged multiple times in 
mammalian cells significantly alters the expression of viral attachment and entry factors, 
specifically the E2 glycoprotein. As a result, these viruses are adapted toward growth and 
infection in mammalian cultures, but have less severe clinical outcomes in vivo. The increased 
binding affinity of E2 to heparan sulfate (HS) on mammalian cells can limit the degree of viral 
dissemination during inoculation, thereby reducing viremia and reducing the neuroinvasiveness 
in some species of alphavirus. In order to avoid this complication, the Klimstra laboratory 
generated cDNA clones based on sequences acquired from human clinical isolates and modified 
them to better represent naturally circulating viruses. These cDNA clones were used to generate 
viral RNA genomes, which were then transfected into cells. Virus stock was then collected from 
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the supernatant of these transfected cells and passaged once using Vero E6 cells. These single 
passage stocks possess the HS binding characteristics of naturally circulating viruses and are 
therefore not attenuated like alphaviruses passaged in cell culture.  
 Due to limited space in the BSL-3, only 3 or four monkeys could be housed within the 
facility at any given time. As a result, most animals were kept at an offsite facility prior to virus 
challenge. When initial pre-infection blood draws were performed on these animals, blood 
samples had to be transported back to the containment facility before being processed. The 
lengthy delay between blood draw and blood processing dramatically reduced the viability of 
some samples for flow cytometry, and created hemolytic errors when used for CBC or blood 
chemistry analysis. Most of these samples were not included in the statistically analysis. 
Fortunately, blood samples were also collected the day of each animal’s exposure after they were 
brought to the BSL-3 facility, but quantities of blood taken at that time varied based on the size 
and hydration of each animal.  
 Since blood PBMCs were initially isolated and freshly stained, a live/dead stain was not 
included in the initial flow cytometry panels. When viably frozen samples were thawed for re-
staining purposes, the use of fixable live/dead stains caused significant compensation problems 
for several important markers. The added live/dead UV stain reduced the separation of CD16 by 
CD14, making the myeloid panel ineffective in identifying subsets within the monocyte 
population. This was due to difficulty separating the close emission spectrum of BV412 and 
V500 when live/dead UV stain was present. Despite ultimately removing the live/dead stain, 
additional efforts were taken to ensure the quality of re-stained cells. Two doublet exclusion 
gates were used, and none of the characteristic signs of lysed cells were present in the final 
stains. Because of their autofluorescence across a broad number of channels, dead cells often 
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cause easily identifiable diagonal populations at medium mean fluorescent intensity. By 
increasing the forward scatter threshold, dead cells and any platelet contamination that was not 
removed during PBMC isolation was excluded from analysis.  
 When cynomolgus macaques were infected with EEEV, it resulted in death in 2 out of 5 
animals. Both lethally infected animals developed a fever roughly 72 hours after inoculation and 
rapidly declined on day 5 post infection. Symptoms included head pressing, rocking, glassy eyes, 
and reduced activity or response to stimuli. Both animals reached the humane endpoint on day 6 
when they became moribund and unresponsive. The three survivors were either asymptomatic or 
developed mild acute febrile symptoms. The collection of neurological tissue from both 
survivors and lethally infected animals revealed no observable gross anatomical changes such as 
calcifications or necrosis during necropsy. Further more detailed histopathology analysis of these 
tissues is ongoing and may demonstrate characteristic encephalopathy. The cerebrospinal fluid 
proved somewhat more difficult to collect in some animals than others, and no CSF was 
successfully collected from the first animal necropsied (M163). Minor contamination of CSF 
with blood could potentially have affected the LEGENDplex assay results.  
 The results from flow staining on PBMCs indicate a rise in CD4 T cells, but a reduction 
of CD8 and CD4/CD8 double positive cells. It is unclear if this shift in the population is the 
result of CD8 cells trafficking to the CNS, or if the virus is causing targeted cell death within 
these populations. The role of CD4/CD8 double positive T cells is unclear in this context. While 
some papers have demonstrated a strong anti-viral function, others have identified cytokine 
production and helper T cell like functions more commonly associated with CD4 cells (61, 62). 
The phenotype of these cells could be elucidated further using live cell sorting and identifying 
intracellular cytokine production, but at this stage it remains ambiguous. Another population that 
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appears altered from pre-infection to necropsy for lethally challenged animals is the NK cell 
population. NK cells are a first line of defense and also produce a number of immune modulatory 
cytokines that are important for inflammation and viral clearance. The loss of these cells could 
indicate migration elsewhere, or depletion as a result of activation, nevertheless it will be 
important to identify trends in NK cells in earlier time points as potential indications of disease 
progression or severity. The next step in these studies will be to compare flow cytometry results 
in PBMC isolated from whole blood to immune cells isolated from the brain to see if the changes 
seen in the peripheral immune populations coincide with changes in the CNS. A preliminary 
look into neural immune cell results suggests a large number of lymphocytes and, to a smaller 
extent, myeloid cells. Unpublished data by JA from our lab, suggests that, of the macrophages 
that are present in CNS tissue, a majority of the classical and intermediate cell populations are 
CCR2+ and CD163+, indicating that they are perivascular in origin and not resident microglial 
cells (63).  
 The large increases in CCR2+ classical and intermediate monocyte subpopulations 
demonstrate a potential drive towards neurotrafficking. It is unclear if these cells are infected and 
serving as Trojan horses assisting neuroinvasion, or if they are responding to pro-inflammatory 
signals produced after viral invasion into the CNS. Research in mice suggests that EEEV is 
incapable of replicating in myeloid cell lineages, although this requires verification in NHP (15). 
The significance of CCR2 and CCL2 (MCP-1) in chronic inflammation and autoimmune 
disorders of the CNS are already well characterized with experimental autoimmune 
encephalomyelitis (64). Whether this is virus driven or inflammation driven, it offers a potential 
target for therapeutic intervention. Targeting CCL2 function is already a technique being 
investigated to prevent metastasis of cancer to bone marrow (65). Aside from homing and 
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migration to infected tissue, CCL2 is also expressed by osteoblasts to recruit osteoclasts for bone 
synthesis. This is especially interesting in the case of EEEV because research in mice suggests 
the viruses initial site of replication is in cells of mesenchymal origin, specifically fibroblasts 
which are in close relation to osteoblasts (15). While this was not a focus at this stage of the 
project, it is possible that the same chemoattractant may play a role in neuroinvasion as well as 
the initial site of replication.  
 It is important to note that flow cytometry analysis of pre-infections samples 
demonstrated a surprising amount of variability between animals and between pre-infection 
collections for animals that had more than one pre-infection blood draw. Future analysis may 
require more pre-infection collection and analysis to strengthen statistical comparisons.   
 The inflammatory cytokine expression in animals lethally infected with EEEV showed 
elevation of MCP-1 (CCL2), IP-10, IL-6, and IL-8. The increased expression of MCP-1 could be 
a possible target for therapeutic agents. IP-10 has many similar functions to MCP-1 in promoting 
migration of immune cells into the CNS. IP-10 interacts with the CXCR3 receptor found on 
activated T cells and NK cells. Given the elevated levels of IP-10 it is worthwhile to explore 
CXCR3 expression on these cell types as a potential factor in neuroinvasion by T cells and NK 
cells. IL-8 is primarily thought to recruit neutrophils, and, in some forms of encephalitis, 
neutrophils are seen in the CSF and regions of the brain. Initial work in the CNS suggests 
lymphocytes and monocytes are the primary infiltrating immune cells during equine encephalitis, 
but the role of neutrophils may need to be examined further if IL-8 is playing a significant role. 
IL-6 is produced by a number of immune cells including T cells and macrophages and promotes 
the acute phase response (66-68). It is a major activator of the febrile response and is present at 
considerably high levels in lethally infected animals. The most interesting trend observed for IL-
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6 expression in the CNS during lethal infection is the relative absence of IL-6 in convalescent 
animals. Although they have lower expression of MCP-1, IP-10, and IL-8 compared to levels in 
lethally infected animals, they still are present at concentrations ranging from several hundred to 
a thousand pg/mL in animals nearly 30 days after infection. IL-6 on the other hand is expressed 
at or below 10pg/mL in every brain region of each convalescent animal. Although it is not clear 
how quickly IL-6 levels return to normal, it could be an important marker for determining 
survival. IL-6 has already been shown to have protective roles in other encephalitis diseases such 
as HSV (69). 
 An important aspect of the project was finding biological surrogates for inflammation in 
the brain. To this end, CSF seemed to mirror CNS inflammation and demonstrated similar 
patterns of upregulation in lethally infected animals and in convalescence. Unfortunately, plasma 
was an inconsistent surrogate with some samples showing no inflammation similar to brain 
regions, or showing altered patterns of upregulation. While CSF collection is moderately 
invasive and difficult, it still demonstrates an accessible and reliable indicator of disease severity 
and progression. When longitudinal samples are collected at later stages of this project, plasma 
may be more indicative of disease progression at earlier time points. All three viruses cause 
viremia shortly after infection. While each virus progresses to this viremia at different rates, the 
peak viremia of each virus may stimulate peripheral inflammation that can serve as quantifiable 
markers of disease severity. As shown in mice (15), VEEV viremia is detectable 6 hrs p.i. and 
peaks at 18 hrs p.i. On the other hand, viremia is not detectable in EEEV until 24 hrs p.i. and 
peaks at 48 hrs p.i. These could represent valuable time points for longitudinal samples in 
identifying quantifiable indicators of disease progression.  
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 Some important concerns regarding the LEGENDplex assay should be mentioned. The 
first assay, which was performed on samples from EEEV infected monkeys, had problems 
regarding clumping when run on the FACSAria flow cytometer. While samples were spun down 
after initial homogenization, they were not spun down again immediately prior to dilution for the 
LEGENDplex assay. As a result, the samples had to be filtered again before being run on the 
flow cytometer. This could explain the slightly larger standard deviation as each sample is run in 
duplicate. This problem was fixed in later plates. Another problem that was encountered was the 
absence or substantial reduction in the number of IL-23 specific beads in the assay performed on 
samples from VEEV infected animals. Given the questionable results for IL-23, it will be 
disregarded in these data sets.  
 For the myeloid stain, it was difficult identifying trends in myeloid dendritic cells and 
Plasmacytoid dendritic cells because of the relative size of these populations. Although a very 
small portion of the monocyte population, they represent unique effector cells. The stain 
confirms our ability to isolate these cells for future live cell isolation or intracellular cytokine 
staining to assess their phenotype and activation in infected animals. Intracellular staining or live 
cell sorting could also be important for lymphocyte populations such as CD4 cells to determine 
their phenotype.  
 In conclusion, analysis by flow cytometry of animals infected with EEEV, VEEV, and 
WEEV suggests shifts in T cell populations (CD4, CD8), NK cells, and the classical and 
intermediate subsets of the broader monocyte population. These changes in classical and 
intermediate cell populations coincide with a substantial increase in the expression of CCR2, a 
receptor responsible for homing and migration to infected tissues. Furthermore, there is an 
increase in expression of MCP-1 (CCL-2) in the brains of lethally infected animals, suggesting a 
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potential for neuroinvasion by monocytes and lymphocytes. Brains of lethally infected animals 
also presented with elevation of IP-10 (CXCL-10), IL-8, and IL-6, with IL-6 elevation being 
unique to lethally challenged animals. These inflammatory markers could represent targets of 
therapeutic treatment, or markers of disease severity and progression. By observing these same 
chemokines/cytokines at earlier time points, we may be able to identify onset of viral 
encephalitis, and likelihood of eventual disease mortality. These cytokines also provide potential 
investigative routes for future studies. Part of the larger project included continual telemetry data 
of temperature and ECG. If these same markers have altered expression in the periphery, they 
could be responsible for certain cardiac abnormalities. IP-10 (CXCL-10) for example, is a 
marker of acute heart injury and infarct, and MCP-1 (CCL-2) is expressed by a number of 
peripheral cell types such as osteoblasts and fibroblasts, which means leukocyte infiltration into 
cardiac or pulmonary tissue may occur as well. In addition, given our knowledge of alphavirus 
promiscuity of cell tropism (especially VEEV), it is impossible to rule out migration of immune 
cells to a variety of tissues. VEEV also commonly causes a systemic pathology compared to 
EEEV and WEEV, which are primarily encephalitis (70). While this study has focused on 
chemokine expression in the brain and suggestive migration to the CNS, it is important to note 
the potential for viral infection in peripheral tissues and subsequent leukocyte homing 
systemically. Finally, flow analysis of CCR2 expression on classical and intermediate monocytes 
from whole blood, combined with LEGENDplex analysis of CSF, may be examples of 
moderately accessible peripheral samples with diagnostic potential for alphavirus induced 
encephalitis. Taken at longitudinal time points these combined data sets could help identify 
important clinical windows during alphavirus infection.   
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